GlassScriptPhysician profile
Brandon Giullian
NPI 1528507183
$3,753.09
in general payments reported to CMS, 2019-2025
28 companies · $545 in 2025
The $545 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,121 · 2023: $1,201 · 2024: $886 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609 · Education: $23.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.54 |
| Education | $23.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $878.33 | 2022-2025 | |
| Janssen Biotech, INC. | $498.26 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $418.65 | 2022-2025 | Krystexxa, Enbrel, Evenity |
| Glaxosmithkline, LLC. | $271.50 | 2022-2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $171.85 | 2022-2024 | Lupkynis |
| Horizon Therapeutics Plc | $160.56 | 2023 | Krystexxa |
| Ucb, INC. | $130.80 | 2022-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $123.10 | 2023 | Acthar |
| Astrazeneca Pharmaceuticals LP | $119.64 | 2023-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $118.00 | 2022 | |
| Abbott Laboratories | $115.00 | 2022 | |
| Pfizer INC. | $113.34 | 2022-2025 | |
| Lilly USA, LLC | $85.81 | 2022-2025 | Mounjaro, Zepbound, Taltz |
| Novartis Pharmaceuticals Corporation | $84.21 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $77.60 | 2024-2025 | Orencia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.39 | 2023-2025 | Cyltezo, Ofev |
| Alexion Pharmaceuticals, INC. | $48.56 | 2024 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.08 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $29.78 | 2025 | Auvelity |
| Viiv Healthcare Company | $28.62 | 2025 | Apretude |
| Organon LLC | $26.48 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $25.67 | 2023 | Arcalyst |
| Genentech USA, INC. | $23.36 | 2024 | Actemra |
| Celltrion USA INC. | $23.07 | 2023 | Yuflyma |
| Fresenius Kabi USA, LLC | $23.05 | 2023 | Idacio |
| Madrigal Pharmaceuticals | $21.38 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $18.33 | 2025 | Voquezna |
| Gilead Sciences, INC. | $15.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Giullian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.